Drugs / GW406381
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00373243 | Oct 2005 → Sep 2006 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00279032 | Sep 2003 → ? | neuralgia, traumatic neuropathy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00113308 | Jun 2005 → Sep 2006 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00120900 | May 2005 → Sep 2007 | osteoarthritis, knee | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00114049 | Dec 2004 → Apr 2005 | dental pulp disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW406381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00279032 ↗ |
| Action | Inhibit | “Cyclooxygenase-2 inhibitor” CHEMBL364804 ↗1“COX-2 Inhibitor” NCT00113308 ↗ |
| Modality | Small molecule | — CHEMBL364804 ↗ |
| Route | Oral | “Administered Orally Once Daily” NCT00113308 ↗ |
| Target | PTGS2 | “Cyclooxygenase-2 inhibitor” CHEMBL364804 ↗ |